Our results demonstrated that the local nutrient composition has a dramatic impact on T cell functionality, with fundamental cellular behaviors being significantly impaired by a reduction in key nutrients such as glucose and oxygen.
Here, we present a proof-of-concept approach for the rapid, non-invasive assessment of immunotherapy response prediction using biomarker imaging signatures.
Here we performed a proof-of-concept study using trastuzumab emtansine (TDM1), a targeted drug for HER2-enriched breast cancer, to demonstrate how biophysical modeling can support dose selection in phase I clinical trials.
The last decade in cancer care has been defined by the rapid emergence (and in some cases, dominance), of monoclonal antibody therapies, where they serve as a critical foundation of oncologic care.
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) is largely dependent on breast cancer subtype, but no clinical-grade model exists to predict response and guide selection of treatment. A biophysical simulation of response to NAC…
Our chief medical officer, Dr. Anuja Antony, represented SimBioSys at the ESMO 2022 conference last month. Among the many exciting advances and developments in the breast cancer field, two topics took center stage: 1) antibody-drug conjugates (ADCs) and 2) human…
SimBioSys® is developing the TumorScope® platform to capture what is truly unique about each patient. The NVIDIA GPU-powered platform takes a holistic and multiscale approach to assess tumor response to therapy. Pulling together all the information that’s painstakingly acquired during…
SimBioSys is one of the 2022 best tech startups in Champaign! “The Tech Tribune staff has compiled the very best tech startups in Champaign, Illinois. In doing our research, we considered several factors including but not limited to: Revenue potential Leadership…
Our team was present at the American Society of Clinical Oncology (ASCO) annual meeting that took place from June 3 – 7, 2022. Perhaps the most impactful moment for breast cancer oncologists and researchers at the conference took place during…
CHICAGO – JUNE 3, 2022 — SimBioSys, the technology company that predicts tumor responses to therapy, announced today it will showcase research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 taking place in Chicago from June 3-7.…
SOLUTIONS
RESOURCES
©SimBioSys